Biovica and Mayo Clinic have entered into an agreement to study the clinical benefit of using DiviTum[®] as a blood-based test, monitoring the tumor response to therapy in patients with metastatic breast cancer.
The main purpose of including DiviTum[®] in studies performed at Mayo Clinic is to evaluate the changes in serum thymidine kinase activity, measured by DiviTum[®], in patients with hormone positive metastatic breast cancer treated with today's standard regimens - including CDK 4/6 inhibitors. DiviTum[® ]measurements at the start of therapy and during treatment will be correlated to patient outcome focusing on the use of DiviTum[® ]as a tool for easy and early evaluation of tumor progression and overall patient survival.
"We are very pleased to collaborate with Mayo Clinic in our ambition to further strengthen our already solid documentation of the value DiviTum[®] can bring to patients being treated for metastatic breast cancer. This collaboration complements our previous studies in this field and will be important in our market introduction of DiviTum® as a tool for the monitoring of patient response to treatments within metastatic breast cancer" says Anders Rylander, CEO Biovica.
DiviTum[®] is an innovative biomarker assay developed with the aim to predict outcome and monitor treatment response in cancer therapy. The test measures the activity of the enzyme thymidine kinase-1 (TK) in a blood sample. In normal cells, TK activity is hardly detectable, but in proliferating cells, the levels increase. Since the degree of TK activity is highly associated with the rate of cell proliferation, it is a particularly suitable biomarker for measuring tumor aggressiveness. DiviTum[®] has in several trials already successfully demonstrated clinical potential in evaluating and monitoring the efficacy of endocrine standard treatments for women with metastatic breast cancer. By providing key information for early identification of those patients not responding or resistant to their on-going treatment, DiviTum[®] presents a non-invasive and efficacious approach to monitoring and predicting responses to standard endocrine therapies.
For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, firstname.lastname@example.org, +46 8 528 00 399. For more information please visit: www.biovica.com.
(c) 2020 Cision. All rights reserved., source Press Releases - English